Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tempest Therapeutics (TPST)
NASDAQ:TPST
RESEARCH TOOLSreports
Holding TPST?
Track your performance easily
TPST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.70 - $6.00
Previous CloseN/A
Volume2.28M
Average Volume (3M)1.68M
Market Cap
$39.07M
Enterprise Value$31.75M
Total Cash (Recent Filing)$18.82M
Total Debt (Recent Filing)$1.73M
Price to Earnings (P/E)―
Beta3.12
Next Earnings
Mar 19, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding43,642,070
10 Day Avg. Volume1,677,610
30 Day Avg. Volume1,677,099
Standard Deviation1.64
R-Squared0.00286
Alpha0.14
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$21.67Price Target Upside2255.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Tempest Therapeutics News
PremiumCompany Announcements
Tempest Therapeutics Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Cost EfficiencyRoche will supply atezolizumab for the upcoming Phase 3 study, offering significant cost savings for Tempest.
Regulatory AdvancementThe company received FDA clearance to proceed with a Phase 3 study of amezalpat in combination with current standard of care, providing a significant regulatory advancement.
Study Timeline OptimizationThe FDA agreed on a statistical plan that includes a pre-specified early efficacy analysis, potentially shortening the study's timeline by eight months.
Bears Say
Cash Flow ConcernsTempest will still require a sizable cash infusion to fully support Phase 3 development.
Financial StabilityThe expected study cost versus current cash balance is a primary reason for the significant weakness in the shares following the survival update and management commentary.
Funding RequirementsTempest will still require a sizable cash infusion to fully support Phase 3 development, which is estimated to cost approximately $100 million.
---
Ownership Overview
8.16% Insiders
0.69% Mutual Funds
1.95% Other Institutional Investors
88.70% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TPST FAQ
What was Tempest Therapeutics’s price range in the past 12 months?
Tempest Therapeutics lowest stock price was $0.70 and its highest was $6.00 in the past 12 months.
What is Tempest Therapeutics’s market cap?
Tempest Therapeutics’s market cap is $39.07M.
When is Tempest Therapeutics’s upcoming earnings report date?
Tempest Therapeutics’s upcoming earnings report date is Mar 19, 2025 which is in 60 days.
How were Tempest Therapeutics’s earnings last quarter?
Tempest Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.362 by -$0.048.
Is Tempest Therapeutics overvalued?
According to Wall Street analysts Tempest Therapeutics’s price is currently Undervalued.
Does Tempest Therapeutics pay dividends?
Tempest Therapeutics does not currently pay dividends.
What is Tempest Therapeutics’s EPS estimate?
Tempest Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Tempest Therapeutics have?
Tempest Therapeutics has 43,642,070 shares outstanding.
What happened to Tempest Therapeutics’s price movement after its last earnings report?
Tempest Therapeutics reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.362. Following the earnings report the stock price went down -10.185%.
Which hedge fund is a major shareholder of Tempest Therapeutics?
Currently, no hedge funds are holding shares in TPST
---
Tempest Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.67 (2255.43% Upside)
$21.67 (2255.43% Upside)
Blogger Sentiment
Bullish
TPST Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.76%
12-Months-Change
Fundamentals
Return on Equity
-691.89%
Trailing 12-Months
Asset Growth
41.06%
Trailing 12-Months
Company Description
Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to treat cancer.
---
TPST Stock 12 Month Forecast
Average Price Target
$21.67
▲(2255.43% Upside)
Technical Analysis
Eloxx Pharmaceuticals
―
Fate Therapeutics
―
Immatics
―
Ocular Therapeutix
―
Rigel
―
X4 Pharmaceuticals
―
Best Analysts Covering TPST
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
+5.84%
reiterated a buy rating 2 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of +5.84% per trade.
---